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ABSTRACT 
 
Podocyte injury is an early event in 
diabetic kidney disease and is a hallmark of 
glomerulopathy. MicroRNA-146a (miR-146a) is 
highly expressed in many cell types under 
homeostatic conditions, and plays an important 
anti-inflammatory role in myeloid cells. However, 
its role in podocytes is unclear. Here, we show that 
miR-146a expression levels decrease in the 
glomeruli of patients with type 2 diabetes (T2D), 
which correlates with increased albuminuria and 
glomerular damage. MiR-146a levels are also 
significantly reduced in the glomeruli of 
albuminuric BTBR ob/ob mice, indicating its 
significant role in maintaining podocyte health. 
miR-146a-deficient mice (miR-146a-/-) showed 
accelerated development of glomerulopathy and 
albuminuria upon streptozotocin (STZ)-induced 
hyperglycemia. The miR-146a targets, Notch-1 
and ErbB4, were also significantly upregulated in 
the glomeruli of diabetic patients and mice, 
suggesting induction of the downstream TGFβ-
signaling. Treatment with a pan-ErbB kinase 
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inhibitor erlotinib with nanomolar activity against 
ErbB4 significantly suppressed diabetic 
glomerular injury and albuminuria in both WT and 
miR-146a-/- animals. Treatment of podocytes in 
vitro with TGF-β1 resulted in increased expression 
of Notch-1, ErbB4, pErbB4 and pEGFR, the 
heterodimerization partner of ErbB4, suggesting 
increased ErbB4/EGFR signaling. TGF-β1 also 
increased levels of inflammatory cytokine MCP-1 
and MCP-1 induced protein-1 (MCPIP1), a 
suppressor of miR-146a, suggesting an autocrine 
loop. Inhibition of ErbB4/EGFR with erlotinib co-
treatment of podocytes suppressed this signaling. 
Our findings suggest a novel role for miR-146a in 
protecting against diabetic glomerulopathy and 
podocyte injury. They also point to Erbb4/EGFR 
as a novel, druggable target for therapeutic 
intervention, especially since several pan-ErbB 
inhibitors are clinically available.  
 
 
Glomerular injury is a major, progressive 
complication of diabetes mellitus and the leading 
cause of end-stage renal disease (ESRD) in the US 
(1). Its histopathologic changes include mesangial 
expansion, glomerular basement membrane 
(GBM) thickening and segmental 
glomerulosclerosis. Podocytes are insulin-sensitive 
cells and are injured early in response to diabetic 
milieu (2,3), suggesting an important role for these 
cells in the development and progression of 
diabetic glomerulopathy. Although recent research 
has elucidated a number of disease associated 
pathways (2,4-10), how diabetic milieu causes 
podocyte injury, foot process effacement and loss 
is still not completely understood. Clinically 
useful targets and therapeutics are also sorely 
needed. Additionally, although histopathologic 
changes from invasive patient biopsies can clearly 
distinguish the extent of kidney damage, 
microalbuminuria is currently the best predictor of 
progression to ESRD in diabetic patients (11,12). 
However, not all patients progress to ESRD at the 
same rate; some progress faster, whereas others 
are resistant to further decline in renal function 
and microalbuminuria is not very helpful in 
stratifying patients in these groups. Thus, 
biomarkers for earlier, more sensitive diagnosis of 
patients who are likely to develop nephropathy or 
progress faster to ESRD are greatly desired, as it 
will greatly improve the disease management and 
patient treatment, and improve clinical trial design.  
MicroRNAs (miRNAs) are a family of 
non-protein-coding RNAs that are ~22-nucleotide 
(22-nt) in length. They sequence-specifically bind 
the 3’-UTR of target mRNAs, where they promote 
mRNA degradation or suppress mRNA 
translation, thus regulating cellular functions. 
miRNAs are endogenously expressed in the 
kidney and several have been found to be up- or 
down-regulated in models of diabetic 
glomerulopathy (reviewed in (13)) and other renal 
diseases (14,15). miR-193a is significantly up-
regulated in podocytes in focal segmental 
glomerulosclerosis (FSGS), where it directly 
targets WT1 transcripts (15). miRNAs miR-21, -
192, -200b, -200c, -216a and -217 are induced in 
the glomerular mesangial cells in animal models 
of diabetic nephropathy (DN), where a number of 
them participate in TGFβ-Smad pathway to 
mediate glomerular damage (13,16-19). Similarly, 
miR-29c is increased in podocytes under high-
glucose (20), where it promotes apoptosis by 
activating Rho kinase via suppression of Spry1. 
Unlike other miRNAs, hyperglycemia down-
regulates miR-93 in podocytes and in glomeruli of 
diabetic animals, thereby increasing VEGF-A 
expression (21). Podocyte expressed miR-21 is a 
feedback inhibitor of TGFb signaling and protects 
against diabetic glomerulopathy (22). These 
studies show that diabetic milieu modulates 
expression of many different miRNAs, and does 
so differentially in the many cells of the 
glomerulus. They also suggest that miRNAs play a 
critical role in the pathophysiology of diabetic 
glomerular injury.  
miR-146a is a key negative regulator of 
innate immune responses in myeloid cells (23,24), 
modulates adaptive immune responses, and has 
been shown to play central roles in many other 
cellular functions, including normal hematopoiesis 
and proliferation of cancer cells (23,25). miR-146a 
is also expressed in various endothelial and 
epithelial cells, although its exact function in these 
cells is much less clear. Oxidative stress/injury of 
endothelial cells leads to up-regulation of miR-
146a, which is shed into exosomes that are then 
taken up by cardiomyocytes to mediate peripartum 
cardiomyopathy (26). In another context, miR-
146a induction limits pro-inflammatory signaling 
in endothelial cells (27). In the context of diabetic 
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injury, a recent study found that miR-146a is 
constitutively expressed in the retinal endothelial 
cells and is down-regulated by high glucose (28). 
In another study, miR-146a levels were reduced in 
the retina, kidney and heart of streptozotocin 
(STZ)-induced diabetic rats. Recently, Natarajan 
and co-workers showed that myeloid cell 
expressed miR-146a levels increase early in a 
mouse model of DN, where it plays an anti-
inflammatory role by suppressing pro-
inflammatory cytokines in macrophages (29). It 
was also recently reported that miR-146a levels 
increase in the kidney in a model of lupus 
nephritis (30). Thus, while there is a growing body 
of research showing that miR-146a expression is 
altered in disease, the role of miR-146a in 
glomeruli is still unclear and needs further 
evaluation. Recent unbiased profiling studies 
reported that miR-146a is highly expressed in 
podocytes (31,32), suggesting that it has an 
important role in maintaining podocyte health. In 
this study, we examined the role of podocytic 
miR-146a in diabetic glomerular injury and 
present our findings below. 
 
RESULTS 
Diabetic patients with reduced glomerular 
miR-146a levels show increased albuminuria and 
glomerular damage-miR-146a is highly expressed 
in podocytes (31,32), suggesting that it might play 
an important role in maintaining glomerular 
health. To examine its role, we correlated the 
expression level of miR-146a in micro-dissected 
glomeruli of kidney biopsies from patients with 
T2D and quantified by qRT-PCR clinical and 
morphometric outcomes (33).  
We observed that a subset of patients with 
low glomerular abundance of miR-146a had high 
albumin to creatinine ratio (ACR) at the time of 
biopsy (Fig. 1A) and at a follow-up appointment 
(Fig. 1B). These data suggest that reduction or loss 
of miR-146a could be a risk factor for glomerular 
damage and albuminuria in patients with diabetes. 
Additionally, we analyzed small RNA-sequencing 
data from micro-dissected glomeruli (glom) and 
tubulo-interstitial compartments  (TI) of 40 kidney 
biopsy samples from this cohort and determined 
that the abundance of the miR-146a cluster 
miRNAs (34) was slightly, but significantly, 
enriched in the glomerular as compared to the TI 
tissue (log2FC [log2(expression in glom) - 
log2(expression in TI)] = 0.6, P < 0.05). 
Furthermore, we associated quantitative data of 
morphometric analyses of glomeruli of these 
samples (described in reference (35)) with miR-
146a abundance and found a significant 
correlation between low miR-146a levels and 
higher mesangial surface area (correlation: 
0.351839, p=0.02) and filtration surface fraction 
(correlation: -0.309166, p=0.03), which are 
parameters associated with increased glomerular 
damage. Furthermore, patients with low relative 
expression exhibited relatively higher ACR at 
follow up compared to subjects with higher miR-
146a levels (Fig. S1). These data support that 
lower miR-146a expression are associated with 
increased glomerular damage and albuminuria in 
diabetic patients.  
To further confirm our findings, we used 
in situ hybridization (ISH) on human and murine 
kidney sections. It showed that miR-146a was 
expressed in the glomeruli of healthy human 
kidney sections (Fig. 2A) and in the healthy wild-
type mouse kidney sections (Fig. 2B). As a 
control, miR-146a-/- mouse glomeruli showed 
complete absence of miR-146a staining (Fig. 2B). 
The glomerular miR-146a levels were 
dramatically reduced in the kidney sections of 
diabetic patients. Podocyte loss causes 
glomerulosclerosis and results in progressive loss 
of renal function in patients with diabetic 
nephropathy (7,36,37). Kidney sections from 
diabetic patients also showed reduced staining for 
podocyte marker synaptopodin (Synpo) (Fig. 2A), 
suggesting that reduction in miR-146a correlates 
with reduced podocyte density and that podocyte 
loss may partially explain the reduced miR-146a 
expression in the glomeruli of diabetic patients. 
The glomerular miR-146a levels were also 
reduced in the kidney sections from the 
albuminuric BTBR ob/ob mice (Fig. 2B-2C), a 
genetic model of T2D (38). Quantitative RT-PCR 
(qRT-PCR) of isolated kidney sections further 
confirmed that miR-146a levels are significantly 
reduced in the albuminuric BTBR ob/ob mice 
(Fig. 2D and Fig. S2). These data confirm that 
miR-146a levels are reduced in the glomeruli of 
diabetic human and mouse kidneys. 
miR-146a targets Notch-1 and ErbB4 are 
upregulated in the diseased glomeruli and in 
podocytes-Among its various molecular targets, 
miR-146a directly targets Notch-1 and ErbB4 
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mRNA (Fig. 3A-B) (26,39-41). Notch-1 
upregulation in podocytes correlates with diabetic 
glomerular injury in experimental models and in 
patients (39,41-43). ErbB4 (v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 4, 
also known as HER4) is a member of the 
epidermal growth factor receptor (EGFR, also 
known as ErbB) family of tyrosine kinase 
receptors that often heterodimerizes with EGFR 
(44). A recent genomewide association study 
(GWAS) with type 1 diabetic nephropathy (T1D) 
patients showed that an intronic SNP in ErbB4 
(rs7588550), which correlates with reduced ErbB4 
expression, was significantly associated with 
protection from T1D (45), suggesting that its 
upregulation in the glomeruli may be deleterious. 
Analysis of publicly available human 
transcriptomic data in Nephroseq from patients 
with diabetes mellitus and healthy controls showed 
that ErbB4 expression was significantly 
upregulated in the diseased kidney sections (Fig. 
3C) (46). Similarly, isolated kidney sections from 
miR-146a-/- animals showed no miR-146a 
expression as compared to the WT (Fig. S3A), and 
an increase in basal expression of its targets ErbB4 
and Notch-1 in podocytes, but no increase in basal 
EGFR levels (Fig. S3B). WB analysis of isolated 
glomeruli and the primary miR-146a-/- podocytes 
further confirmed increased expression of ErbB4 
over the glomeruli and the podocytes from WT 
animals (Fig. S4). Histochemical and 
immunofluorescence staining of kidney sections 
from diabetic patients and the diabetic BTBR 
ob/ob mice also showed upregulation of miR-146a 
targets Notch-1 and ErbB4 in the diseased 
glomeruli versus healthy controls (Figs. 3D-3F). 
We also observed glomerular upregulation of 
ErbB4’s heterodimerization partner EGFR in these 
samples, confirming similar findings by others 
(47-50). Co-staining with podocyte marker 
synaptopodin showed that the increase in their 
expression co-localized within podocytes in the 
glomeruli. Furthermore, expression of miR-146a 
targets Notch-1 and ErbB4 in the micro-dissected 
glomeruli of diabetic patients also showed 
negative association with miR-146a expression 
(Notch-1, R = -0.273; ErbB4, R = -0.108), 
providing additional confirmation of the 
immunofluorescence findings. 
To confirm direct targeting of Notch-1 and 
ErbB4 transcripts by miR-146a, we utilized a 
luciferase reporter vector encoding the 3’-UTR of 
human ErbB4 or Notch-1 and mutated vectors 
containing mismatches in the predicted miR-146a 
binding site in each, respectively (Fig. S5) (26). 
Co-transfection of pre-miR-146a and the ErbB4 or 
the Notch-1 3’-UTR plasmids in HEK293T cells 
resulted in a significant decrease in the luciferase 
activity as compared with cells co-transfected with 
pre-miR-146a and the mutated ErbB4 or Notch-1 
3’-UTR plasmids (Fig. 3G). Furthermore, 
retrovirus-mediated overexpression of miR-146a 
in WT podocytes also resulted in reduction of 
ErbB4 expression (Fig. S6). Together, these data 
suggest that miR-146a, by directly modulating the 
expression of its targets ErbB4 and Notch-1, may 
have an important regulatory role in podocytes and 
that miR-146a down-regulation may lead to 
transcriptional up-regulation of these proteins, 
resulting in glomerular damage in diabetes.  
STZ accelerates glomerulopathy in miR-
146a-/- animals and is attenuated by erlotinib-To 
further investigate the role of miR-146a in 
glomerular function in vivo, we induced 
hyperglycemia in miR-146a-/- animals using STZ 
(5). STZ treatment induced similar levels of 
hyperglycemia (Fig. 4A) and body weight decline 
(Fig. 4B) in both C57BL/6 wild-type (WT) and the 
miR146a-/- animals that persisted throughout the 
course of this study, confirming recent findings 
(29). While the diabetic WT animals showed a 
slow increase in albuminuria (5,51,52), the 
diabetic miR-146a-/- animals showed a more rapid 
increase and significantly higher level of 
albuminuria (Fig. 4C), suggesting that miR-146a 
deletion greatly accelerates the renal decline in 
animals, also in line with recent findings (29). 
Histopathology and morphometric analyses of the 
kidney sections showed significant mesangial 
sclerosis in the diabetic WT and miR-146a-/- 
animals as compared to the healthy controls (Fig. 
5A-5B), and an expected increase in leukocyte 
infiltration with STZ treatment (Fig. S7) (29). 
Electron microscopy (EM) based analyses showed 
significant foot-process effacement (Fig. 5C). The 
receptor tyrosine kinase (RTK) EGFR is expressed 
in the tubules and the glomeruli (53) and promotes 
TGFβ signaling in diabetes (48-50,54). 
Immunofluorescence staining of kidney sections 
showed increased expression of EGFR along with 
increased Notch-1 and ErbB4 in the glomeruli of 
diabetic WT and miR-146a-/- animals, as compared 
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to healthy controls (Fig. 6A-6B). Since the ErbB4 
expression increased in both WT and miR-146a-/- 
diabetic glomeruli, we tested whether treatment 
with inhibitor erlotinib would offer protection 
from renal decline. Most small molecule inhibitors 
target multiple members of the EGFR family and 
no selective ErbB4 inhibitors are currently 
available. However, the EGFR inhibitor erlotinib 
also inhibits ErbB4 with nanomolar affinity (IC50 
= 230 nM) (55). Therefore, we tested whether 
ErbB4 inhibition with this pan-ErbB inhibitor will 
have efficacy in this model. Administration of 
erlotinib to the diabetic animals did not change the 
level of hyperglycemia in either WT or the miR-
146a-/- animals (Fig. 4A). However, erlotinib 
treatment protected both the WT animals, as was 
recently shown (49,54), and the miR-146a-/- 
animals from development of albuminuria (Fig. 
4C), and resulted in reduced leukocyte influx in 
both (Fig. S7). Furthermore, analysis of kidney 
sections of erlotinib-treated diabetic mice showed 
a significant reduction in glomerular mesangial 
sclerosis and foot process effacement (Fig. 5A-
5C), and immunofluorescence analysis showed a 
significantly reduced expression of EGFR, Notch-
1 and ErbB4 in the glomeruli of treated WT and 
miR-146a-/- animals (Fig. 6A-6B). ISH with a 
miR-146a probe (Fig. 7A) and 
immunohistochemical (IHC) analysis with anti-
WT1 antibody (Fig. 7B) showed that expression of 
miR-146a and WT1 was reduced in the STZ-
treated, diabetic WT animals, but that the 
glomerular miR-146a and WT1 expression was 
largely preserved in the kidney sections of the 
animals treated with erlotinib. These data suggest 
that ErbB4 pathway is upregulated in the 
glomeruli of diabetic animals and that clinically 
available pan-ErbB inhibitors are potential 
therapeutics for reducing the glomerular damage. 
TGF-β1 induces ErbB4 expression and 
signaling-Transforming growth factor beta 1 
(TGF-β1) is a pleotropic cytokine and a member 
of the TGFβ superfamily. It mediates podocyte 
damage and glomerulosclerosis, and is a key 
mediator of glomerular injury in diabetes (56,57). 
Actin cytoskeleton in podocytes is a critical link 
between various signaling components and the 
cellular receptors, while playing an essential role 
in providing stable architectural support to the cell. 
Immunofluorescence microscopy showed that 
TGF-β1 induced rearrangement of the actin 
cytoskeleton resulting in loss of stress fibers in 
podocytes (58,59), a hallmark of cellular damage, 
and that this loss of stress fibers was prevented by 
co-treatment with erlotinib (Fig. 8A), suggesting a 
link between TGF-β1 signaling and ErbB4. TGF-
β1 imparts its intracellular effects via Smad and 
MAPK signaling pathways and treatment of 
podocytes with TGF-β1 showed increased 
phosphorylation of Smad2/3, Erk and p38, and 
expression of cleaved Notch-1, in addition to its 
auto-induction (Fig. 8B) (56,57,60,61). We also 
found that TGF-β1 increased expression of ErbB4 
and increased ErbB4 phosphorylation (Y984), 
suggesting that it elicits intracellular signaling. It 
also enhanced EGFR phosphorylation in the 
treated cells (at three different sites Y845, Y1068 
and Y1173), but not the level of EGFR. Co-
immunoprecipitation (Co-IP) assays using over-
expression vectors in HEK 293 cells confirmed 
that ErbB4 and EGFR heterodimerize on the cell 
surface (Fig. S8), suggesting that their observed 
increase in phosphorylation is likely due to 
ErbB4/EGFR heterodimerization. miR-146a-/- 
podocytes showed basally increased expression of 
ErbB4, cleaved Notch-1 and TGF-β1, and 
increased phosphorylation of Smad2/3, Erk, p38, 
ErbB4 and EGFR (Fig. 8B), suggesting that the 
ErbB4/EGFR pathway is induced in the absence of 
miR-146a. Co-treatment of WT and miR-146a-/- 
podocytes with erlotinib to antagonize 
ErbB4/EGFR signaling showed a marked 
reduction in the deleterious expression changes 
induced by TGF-β1. Monocyte chemoattractant 
protein-1 (MCP-1) is a pro-inflammatory 
chemokine that is induced upon RTK-induced 
STAT3 activation (62). In turn, it increases 
expression of MCP1-induced protein 1 (MCPIP1), 
which inhibits miR synthesis and suppresses miR-
146a (63,64). We confirmed that TGF-β1 
treatment induced MCP-1 in podocytes (65) and 
that erlotinib suppressed the TGF-β1-mediated 
increase in MCP-1 (Fig. 9), suggesting that MCP-
1 induction is downstream of EGFR/ErbB4. 
Similarly, TGF-β1 increased expression of 
MCPIP1, which was suppressed by erlotinib (Fig. 
8B-8C, bottom panel). In sum, these data suggest 
that diabetic milieu suppresses miR-146a levels in 
podocytes via induction of MCP1 and MCPIP1, 
and that reduced miR-146a results in upregulation 
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of its molecular targets Notch-1 and ErbB4, which 
also enhances MCP1, thus inducing an autocrine 
loop (Fig. 10). 
 
DISCUSSION 
Podocyte damage and dysfunction is a 
hallmark of glomerular diseases and is evident in 
diabetic glomerulopathy. MicroRNAs play a 
significant role in maintaining podocyte health and 
in the pathogenesis of podocytopathies. This study 
provides evidence, for the first time, that miR-
146a protects podocytes against diabetic injury 
and that its loss exacerbates diabetic 
glomerulopathy. While miR-146a is most 
commonly associated with innate immune cells 
and has primarily been studied in that context, it is 
also highly expressed in healthy podocytes 
(31,32). Our surprising finding that miR-146a 
expression is significantly reduced in the 
glomeruli of diabetic patients and diabetic 
animals, and that its reduction in glomeruli 
correlates with glomerular damage, support its role 
in maintaining glomerular health. Furthermore, 
patients with low glomerular miR-146a levels 
show significantly faster decline in renal function, 
as compared to patients with relatively higher 
levels. Concomitant with changes in miR-146a 
levels, we also observed upregulation of direct 
mRNA targets of miR-146a, namely Notch-1 
(39,40) and ErbB4 (26,41) (and its binding partner 
EGFR), in the glomeruli of both diabetic human 
and mouse kidneys, suggesting a direct molecular 
link. STZ-induced hyperglycemia significantly 
accelerated development of albuminuria and 
glomerular injury in miR-146a-/- animals, as 
compared to the WT mice, along with an increase 
in glomerular expression of Notch-1 and ErbB4. 
Blocking ErbB4 with a known antagonist, 
erlotinib, protected animals from the development 
of albuminuria and significantly reduced 
glomerular damage. This suggests that miR-146a, 
by directly modulating the expression of Notch-1 
and ErbB4, may have an important regulatory role 
in podocytes. Mechanistic studies with cultured 
podocytes showed that treatment with TGF-β1, a 
mediator of diabetic podocyte injury in vivo, 
increased expression of Notch-1 and ErbB4. TGF-
β1 treatment also increased phosphorylation of 
ErbB4 and its heterodimerization partner EGFR, 
activating downstream RTK signaling, which has 
previously been shown to induce pro-
inflammatory pathways via induction of STAT3 
(62). Indeed, TGF-β1 increased levels of MCP-1 
in podocytes as well as auto-induction of TGFβ. 
TGF-β1 also increased levels of MCPIP1, a 
ribonuclease that is upregulated by MCP-1 and 
antagonizes miR-146a in cells (63,64). These data 
suggest that miR-146a acts as a molecular break 
on ErbB4 signaling via suppression of ErbB4 
levels in podocytes, and that diabetic milieu, via 
TGF-β1, activates a feed-forward loop, where 
MCP-1 and MCPIP1 reduce miR-146a levels, 
thereby activating ErbB4 signaling, which 
increases autocrine synthesis of MCP-1, further 
reducing the miR-146a levels (Fig. 10). Data 
showing that erlotinib treatment counteracts this 
ErbB4-mediated MCP-1 autocrine loop provides 
further evidence for this pathway being active in 
mediating diabetic injury in podocytes. Our 
findings suggest a novel role for miR-146a in 
pathogenesis of diabetic glomerulopathy and as a 
biomarker for disease progression. They also point 
to Erbb4 as a novel target for therapeutic 
intervention. 
To date, miR-146a has primarily been 
defined by its role in innate immune system, as a 
negative regulator of pro-inflammatory NFkB 
signaling (23,24). Its currently defined role in 
modulating kidney injury has also been limited to 
its function in the immune cells. Indeed, a recent 
study by Natarajan and co-workers nicely showed 
that myeloid cell expressed miR-146a levels 
increase early during DN in mice due to increased 
influx of miR-146a-expressing myeloid cells, and 
that miR-146a-/- mice show accelerated DN due to 
both an increase in macrophage influx in the 
kidney and an increase in the pro-inflammatory 
phenotype of the infiltrated macrophages in the 
knockout (29). However, whether podocyte-
expressed miR-146a has any role in podocyte 
function has never been studied before. The results 
presented here clearly show that the podocytic 
miR-146a also has protective role against diabetic 
injury, complementing the previous studies. 
However, because our studies here utilized the 
global miR-146a-/- (as podocyte-specific miR-
146a-/- are not available), one could argue that 
myeloid cell expressed miR-146a, due to its role in 
regulating pro-inflammatory pathways, is the 
dominant cell type for the observed effects. 
However, if macrophage-derived miR-146a was 
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the sole driver of disease pathogenesis, one would 
expect to find increased miR-146a levels in the 
tissue from patients with diabetic kidney disease 
due to increased influx of macrophages. As shown 
in Figures 1 and S1, we find the exact opposite, in 
that lower glomerular levels of miR-146a associate 
with increased proteinuria and glomerular damage. 
This, in combination with the recent study looking 
at its role in macrophages (29), suggests both a 
podocyte-intrinsic and -extrinsic role for this 
microRNA in diabetic glomerular injury.  
Studies presented here also provide a 
potential mechanistic understanding behind the 
previously described role of Notch-1 in diabetic 
glomerular injury. Notch-1 is a member of a 
family of four transmembrane proteins that are key 
developmental proteins (66). While the Notch 
pathway is indispensable for renal glomerular and 
proximal tubule development (67-69), Notch-1 
expression is down-regulated in healthy adult 
kidneys. However, Notch-1 is upregulated in the 
glomeruli of diabetic patients and in experimental 
models of diabetic nephropathy (42,43). Podocyte-
specific over-expression of ICN is sufficient to 
induce podocyte injury and glomerulosclerosis, 
suggesting that Notch-1 plays a critical role in the 
pathogenesis of diabetic glomerulopathy. 
However, a detailed molecular mechanism behind 
how Notch-1 is kept in check in healthy podocytes 
and how it is upregulated during diabetic injury is 
not clear. The data presented here suggests that 
miR-146a may be an important microRNA 
regulating levels of Notch-1 in podocytes. 
Prior studies have also shown that EGFR 
phosphorylation and activation in podocytes 
promotes glomerular injury in response to 
inflammatory and diabetic stimuli, and that its 
pharmacologic blockade or podocyte-specific 
deletion is protective (47-50). EGFR 
phosphorylation leads to induction of TGFb-
Smad-2/3 signaling, resulting in podocyte 
apoptosis. However, whether induction and 
activation of EGFR’s heterodimerization partner 
ErbB4 in podocytes plays a role in disease 
pathogenesis and what that role might be has not 
been described before. The results presented here 
suggest that both proteins are induced in the 
diabetic glomeruli. Similarly, the pan-ErbB kinase 
inhibitor erlotinib binds to EGFR with a 
significantly higher affinity (2 nM) than ErbB4 
(55) and has been shown to protect against DN 
(47-50), which might suggest that the efficacy of 
erlotinib observed here is likely due to its 
inhibition of EGFR over ErbB4, suggesting that 
EGFR is the main culprit in disease pathogenesis. 
However, here we find that, at least with the TGF-
β1 treatment of podocytes in vitro, ErbB4 levels 
increased in cells without affecting levels of 
EGFR, suggesting that ErbB4 upregulation has 
pathogenic relevance. TGF-β1 treatment also 
increased phosphorylated forms of both EGFR and 
ErbB4, suggesting that the heterodimeric receptor 
signals together for the induction of downstream 
signaling pathways and that erlotinib inhibits this 
signaling. Still, the studies presented here cannot 
rule out that the protective effects of erlotinib are 
solely due to it inhibiting EGFR. Future studies 
with tissue specific ErbB4 knockouts and 
knockins, as well as any compounds that 
selectively target ErbbB4 over EGFR will help 
clarify this better. 
Finally, ErbB4, like Notch-1, is a key 
developmental protein, that is expressed in 
developing nephrons and plays a role in epithelial 
cell proliferation and tubulogenesis, and is present 
in podocytes (70-73). It shows minimal expression 
in the adult kidney. While ErbB4 is highly 
upregulated in the kidneys with polycystic kidney 
disease (PKD), its genetic deletion protected 
animals from PKD, suggesting a complex and 
unclear role for ErbB4 in development and disease 
pathogenesis (74). Here, our results show that 
ErbB4 is upregulated in diabetic glomeruli and in 
podocytes, suggesting that it plays a role in 
diabetic podocyte injury. Additionally, we find 
that ErbB4 shows higher expression at basal level 
in miR-146a-/- podocytes, suggesting regulation by 
miR-146a. These results also provide a potential 
explanation for the recent findings from a GWAS 
study with >11,000 type 1 diabetes (T1D) patients 
aiming to look at an association for DN as a 
primary phenotype, which reported that an intronic 
SNP in ERBB4  (rs7588550, P = 2.1×10−7) that 
results in reduced expression of ErbB4 provides 
the strongest protective effect (45). 
In summary, our findings suggest a novel 
role for miR-146a in pathogenesis of diabetic 
glomerulopathy and as a biomarker for disease 
progression. They also point to ErbB4 as a novel 
target for therapeutic intervention early in the 
disease process. Given that several ErbB kinase 
inhibitors, that also target ErbB4, are in the clinic 
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as potent anti-cancer agents, our findings also 
suggest that such clinically available agents are 
potential therapeutics for diabetic kidney disease. 
 
EXPERIMENTAL PROCEDURES  
Materials-The cell culture reagents were 
purchased from Life Technologies (Carlsbad, CA), 
except for the fetal bovine serum (FBS), which 
was from Hyclone (Logan, UT). Alexa Flour568-
labeled phalloidin and HCS CellMask blue were 
obtained from Life Technologies (Carlsbad, CA). 
Rat tail Collagen I, was from Sigma-Aldrich (St. 
Louis, MO) and mouse recombinant interferon-
gamma was from Cell Sciences (Canton, MA). 
Recombinant TGF-β1 was from R&D Systems 
(Minneapolis, MN) and erlotinib was from LC 
Laboratories (Woburn, MA). The list of primary 
antibodies used in Western blotting is as follows: 
The polyclonal goat anti-synaptopodin antibody 
(P-19) and rabbit anti-ErbB4 antibody (C-18) were 
from Santa Cruz (Dallas, TX); rabbit anti-EGFR 
was from Millipore (#06-847, Darmstadt, 
Germany); polyclonal rabbit anti-notch1 was from 
Rockland (#100-401-407, Limerick, PA); rabbit 
anti-podocin antibody was from Sigma-Aldrich 
(St. Louis, MO). Antibodies against cleaved 
Notch1 (Val1744) and anti-GAPDH (6C5) were 
obtained from Abcam (Cambridge, MA). The anti-
EGFR (D38B1), anti-p-EGFR (Y845), anti-p-
EGFR (Y1068) (D7A5), anti-p-EGFR (Y1173) 
(53A5), anti-p-ErbB4 (Y984), anti-ERK (137F5), 
anti-p-ERK (T202/Y204), anti-p38, anti-phospho-
p38 (T180/Y182) (28B10), anti-Smad2/Smad3, 
anti-p-Smad2 (S465/467)/Smad3 (S423/425) 
(D27F4), and anti-TGF-β1 antibodies were from 
Cell Signaling (Danvers, MA). Retroviral vector 
for ectopic miR-146a expression has been 
described previously (25). Control vector #LV015-
G encoding a scrambled sequence was from 
Applied Biological Materials (Richmond, BC, 
Canada). 
Animals-Animal care and procedures were 
approved by the Institutional Animal Care and Use 
Committee (IACUC) and were performed in 
accordance with institutional guidelines. The 
C57BL/6J wild-type (WT) and the miR-146a-/- 
(cat. No. 016239) (75) mice were purchased from 
the Jackson Laboratory (Bar Harbor, ME).  
Blood glucose and urinary albumin and 
creatinine measurements-Blood glucose was 
measured from blood obtained from tail vein of 
mice by using FreeStyle Freedom lite glucometer 
(Abbott, Chicago, IL). For urinary albumin and 
creatinine measurements, spot urine samples were 
collected non-invasively from mice. Urinary 
albumin and creatinine concentrations were 
measured using a mouse albumin ELISA (Bethyl 
Laboratories, Montgomery, TX) and a creatinine 
assay (Exocell, Philadelphia, PA), respectively. 
Urine albumin:creatinine ratios were then 
calculated. 
Primary Podocyte Isolation-Primary 
mouse podocytes were isolated according to 
published protocols (76). Briefly, kidneys were 
collected from 8-16 week old mice. Freshly 
collected kidneys were mashed with cold PBS 
through test sieves (Retsch, Newtown, PA) whose 
pore diameters are 180 µm, 75 µm, and 52 µm, 
sequentially. Glomeruli in the sieve of 52 µm 
pores were collected in PBS. After spinning down, 
they were resuspended with RPMI 1640 medium 
containing 10% FBS and were plated on collagen I 
coated plates for 14 days. Cells were trypsinized 
and filtered with 40 µm strainer. Filtered cells 
were spun down and seeded on collagen I coated 
plates for culturing.  
Cell culture and immunofluorescence 
staining-Immortalized murine podocytes have 
been described and were cultured according to 
published protocols (77,78). Cells were transduced 
with miR-146a or scrambled sequence containing 
vectors as previously described (25). For 
immunofluorescence staining of cultured cells, 
cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, and were 
blocked with 5% bovine or donkey serum (Sigma). 
After incubating with primary antibodies, 
secondary antibodies and/or Alexa 568-conjugated 
phalloidin (Life Technologies) were incubated 
with cells. Stained cells were imaged with a Zeiss 
700 LSM confocal microscope (Zeiss, Hartford, 
CT) and Opera Imaging System (Perkin Elmer, 
Waltham, MA), as described (58). 
For tyramide signal amplification (TSA) 
mediated immunofluorescence co-staining of 
synaptopodin with the markers NOTCH-1, EGFR, 
or ErBB4 in formalin fixed tissue sections, human 
or mouse kidney tissue was fixed in formalin and 
embedded in paraffin for further processing. 
Tissue sections (3 µm) were deparaffinized and 
hydrated through xylenes and graded alcohol 
series before acidic antigen retrieval (#H-3300, 
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Vector Labs). Sections were incubated in 0.1% 
Triton-X for 10 mins at RT, washed, and 
incubated with blocking buffer for 1 hr at RT. 
Sections were then incubated with primary 
antibodies in blocking buffer at 4°C overnight. 
Tissues were washed and incubated with 0.3% 
hydrogen peroxide for 30 mins at RT to block 
endogenous peroxidase activity. Sections were 
then incubated with blocking buffer containing 
HRP labeled secondary antibody polymer (#MP-
7401, Vector Lab) and donkey anti-goat AF488 
(#A-11055, Thermo Fisher) for 30 mins at room 
RT. Sections were washed, incubated with TSA 
reagent for 10 mins, washed and stained with 
DAPI for 3 mins at RT.   Stained tissues were 
imaged with a Zeiss 700 LSM confocal 
microscope and the images were quantified and 
analyzed using Image J software (NIH, Bethesda, 
MD).  
Electron Microscopy Imaging and 
Quantification-For transmission electron 
microscopy (TEM), tissues were fixed, embedded, 
sectioned, and stained as previously described 
(79). Briefly, kidney sections from 25 week old 
miR-146a-/- mice treated with vehicle (sodium 
citrate), STZ, or STZ and erlotinib were sectioned 
and imaged as recently described (58). Images 
were acquired using Zeiss SIGMA HD VP 
electron microscope (Zeiss). TEM micrographs 
were analyzed using SmartTiff software (Zeiss). 
To reduce potential bias, the analyses were 
performed in a blinded fashion, where the tissues 
were sectioned, stained, imaged and analyzed by 
an independent observer that was blinded to the 
tissue identity. Furthermore, micrographs selected 
at random from three different glomeruli per 
condition were used for analysis. Length of GBM 
was measured using the point-to-point tool on 
images acquired at 5000x magnification. Each 
secondary foot process was tallied manually and 
divided into total GBM length to calculate number 
of foot processes per micron of GBM. This ratio 
was used as an indicator of foot process 
effacement.    
Luciferase Plasmids-For the luciferase 
assay, 3’ UTR of wild type or mutated ErbB4 or 
Notch-1 were cloned into luciferase reporter 
plasmid pmirGLO plasmid (Promega, Madison, 
WI) following manufacturer’s instructions. The 
inserted 3’ UTR sequences are shown below (also 
in Fig. S5). 
Wild type Erbb4 3’ UTR:  
AAGAAATGTCCACATAACTTCGTGGTAGA
TTCCAGTTCTTGTGTACGAGCCTGCCCTAG
T,  
Mutated Erbb4 3’ UTR:  
AAGAAATGTCCACATAACTTGCTAAAAGA
TCCCAATTCTTATGTACGAGCCTGCCCTAG
T,  
Wild type Notch1 3’ UTR:  
GGAAAAACATATCTGTTCCAAGAAAATAA
ACTAGTTCTCAGAGCCTTGATTTTCCTGG,  
Mutated Notch1 3’ UTR:  
GGAAAAACATATCTGTTCGATCTACTTACA
CTGGATCTCAGAGCCTTGATTTTCCTGG. 
Luciferase Assay-MicroRNA precursors 
pre-miR 146a-5p (hsa-miR146a-5p, cat. no. 
AM17100, Life Technologies, Carlsbad, CA) or 
the control precursor pre-miR Negative Control #1 
(AM17110, Life Technologies) were transfected 
into HEK293T cells in 96 well cell culture plates 
using Lipofectamine 3000 (Life Technologies, 
Carlsbad, CA) and following manufacturer’s 
protocols. After 24h, the cells were further 
transfected with reporter luciferase expression 
plasmids (pmirGLO, Promega, Madison, WI) 
containing sequence from wild type or mutated 
ErbB4 3’ UTR or Notch1 3’ UTR as above (Fig. 
S5), along with the beta-galactosidase expression 
plasmid (80). To quantify luciferase activity in 
each well, cells were washed with PBS and lysed 
using supplied lysis buffer 48h after plasmid 
transfection. Cellular lysates were used in a 
luciferase assay and a beta-galactosidase assay. 
The luminescence activity in the lysate was 
measured 15 minutes after mixing the cell lysate 
with a luciferase substrate (Promega). The beta-
galactosidase activity in the lysate was measured 
by incubating the cell lysate with assay buffer 
containing ONPG (Sigma) for 30 minutes and, 
subsequently, using sodium carbonate to stop the 
reaction and measuring absorbance at 420 nm. 
Luminescence values were normalized to each 
lysate’s absorbance readings at 420nm (beta-
galactosidase activity).  
Western Blotting-Podocytes were cultured 
in 100-mm dishes under non-permissive 
conditions at 37°C without γ-interferon for 10-14 
days to promote differentiation. Differentiated 
podocytes were maintained in serum-free medium 
overnight before treating with recombinant mouse 
TGFβ1 (5 ng/mL) and erlotinib (10 µM) for 24 
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hrs. Subsequently, cells were washed with ice-cold 
PBS and lysed using cold lysis buffer (RIPA 
containing EDTA and EGTA, Boston 
Bioproducts, Ashland, MA) supplemented with 
protease inhibitor (Roche Life Science, 
Indianapolis, IN) and phosphatase inhibitor 
(Sigma-Aldrich, St. Louis, MI). Cell lysates were 
incubated on ice for 30 min (with intermittent 
vortexing) and centrifuged in a tabletop centrifuge 
at 13,000 rpm for 15 min at 4°C. Supernatants 
were carefully transferred to new microcentrifuge 
tubes and protein concentrations were determined 
by Bradford assay (Bio-Rad, Hercules, CA). Equal 
amounts of protein from each sample were loaded 
to Nu-PAGE Novex 4–12% Bis-Tris gels (Life 
Technologies, Carlsbad, CA) and transferred to an 
Immobilon-P PVDF membrane (EMD Millipore, 
Billerica, MA). The membrane was blocked with 
5% BSA (ThermoFisher Scientific) in TBS-
Tween-20 (0.05%) (Boston Bioproducts, Ashland, 
MA), followed by incubation with primary 
antibodies at 4°C overnight. After washing with 
TBS containing Tween-20, the membrane was 
incubated with a secondary antibody conjugated to 
horseradish peroxidase (Promega, WI) for 1 h at 
room temperature. Blots were developed using 
SuperSignal West Pico chemiluminescent 
substrate (ThermoFisher Scientific) using X-ray 
films (Kodak, Rochester, NY) and using an AX-
700LE film processor (Alphatek, Houston, TX). 
Co-immunoprecipitation assay-HEK293T 
cells were transfected with mammalian expression 
plasmids coding for 20µg EGFR (11011, 
Addgene), or 20µg ErbB4 (29536, Addgene) or 
both using Lipofectamine 3000 and OptiMEM 
(Life Technologies) in 100mm cell culture dishes 
following manufacture’s protocols. After 48 hours, 
cells were lysed with NP40 lysis buffer (Boston 
Bioproducts, Ashland, MA) supplemented with 
protease inhibitor (Roche Life Science, 
Indianapolis, IN) and phosphatase inhibitor 
(Sigma-Aldrich, St. Louis, MI). Total cell lysates 
containing 800 mg protein were incubated with 
primary antibodies (either rabbit isotope control 
antibody or anti-ErbB4 antibody (Santa Cruz 
Biotechnology)) overnight at 4°C. Subsequently, 
protein G beads (Life Technologies) pre-blocked 
with BSA were added to the lysate-antibody 
mixture and incubated for 4 hours at 4°C. Next, 
the beads were thoroughly washed and bound 
protein was eluted using Laemmli buffer (Bio-
Rad) and boiled for 5 minutes. Eluted proteins 
were used for western blotting, as described 
above. 
miRNA analysis by qRT-PCR-MicroRNA 
analysis was performed using qRT-PCR protocol 
as previously described.(22) Briefly, total RNAs 
or miRNA fractions were isolated from mouse 
kidney tissue or from mouse podocytes using 
miRNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer provided protocol 
and quantified using NanoDrop (ThermoFisher). 
The isolated RNAs (0.5-2.0 µg) were used as 
template for cDNA synthesis using High Capacity 
cDNA Archive Kit (Life Technologies). qRT-PCR 
was performed using CFX96TM Real-Time 
System (Bio-Rad) and the following TaqMan® 
Gene expression assays (Life Technologies) were 
used: miR146a (A25576, ID: 478399_mir), 
miR361 (A25576, ID: 478056_mir), and Gapdh 
(4331182, ID: Mm99999915_g1). For analysis, 
the fold change in mRNA levels between various 
groups was determined after normalizing each 
mRNA expression level with Gapdh (2-ΔΔ Ct 
method). The fold change in miR-146a levels 
between various groups was determined after 
normalizing miR-146a expression level in each 
group with levels of miR361. 
STZ-induced hyperglycemia-
Hyperglycemia was induced in the wild type 
C57B/L6 and the miR-146a-/- mice according to 
published protocols (5). Briefly, 8-10 week old 
male mice were administered two doses of STZ 
(Sigma-Aldrich) (125 mg/kg body weight) in 50 
mM sodium citrate buffer, pH 4.5 
intraperitoneally on days 1 and 4. Glucose levels 
from tail blood were measured with an Accu-
Check glucometer (Roche Life Science). Animals 
with glucose levels >400 mg/dL on two 
consecutive measurements were regarded as 
hyperglycemic. The mice received no insulin 
during the study period. Urinary albumin and 
creatinine were analyzed before injection and 2, 4, 
6, 8, 10, 12, 14, and 16 weeks after the STZ 
injection. Erlotinib (37 mg/kg), in Saline 
containing 1% Tween-20, 25% kolliphor and 2.5% 
DMSO, was administered intraperitoneally every 
other day starting at week 4 post-STZ to a group 
of mice, according to literature protocols. Kidneys 
were harvested and processed for histological and 
ultrastructural analyses after 16 weeks post-STZ. 
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Tissue histochemical and 
immunofluorescence staining-Mouse kidneys were 
harvested after perfusion with PBS. One section of 
the removed kidney was fixed in 10% formalin 
and embedded in paraffin and another part was 
immediately snap frozen in OCT embedding 
compound on liquid nitrogen and stored at -80°C. 
Paraffin embedded sections (4 µm) were stained 
with hemotoxylin-eosin (H&E), periodic acid-
Schiff (PAS), or Masson’s trichrome. Stained 
slides were blindly evaluated by an experienced 
pathologist and scanned using Aperio software 
(Leica, Buffalo Grove, IL). Fibrosis was indicated 
as a percent of tissue area stained blue with 
Masson’s trichrome. Quantification for glomerular 
volume and mesangial expansion was performed 
according to published methods using ImageJ 
software (NIH, Bethesda, MD) (29). Glomerular 
podocyte density was determined for using anti-
WT1 (sc-15421, Santa Cruz) 
immunohistochemical staining and manual 
counting of WT1-positive cells from at least 5 
glomeruli per sample (n=3) in a blinded fashion. 
CD11b-positive cells were analyzed by 
immunohistochemical staining using anti-CD11b 
antibody (ab75476, Abcam). For 
immunohistochemical staining, tissue sections 
were deparaffinized in xylene and rehydrated 
through descending concentrations of ethanol and 
subjected to antigen retrieval by steam heating in 
an acidic pH solution (Citrate-based, Vector 
Laboratories). Subsequently, sections were 
incubated in 0.3% hydrogen peroxidase in water 
for 30 mins followed by blocking (4% FBS, 4% 
BSA, 0.4% fish gelatin) at room temperature for 1 
hr. Thereafter, sections were incubated with 
primary antibodies at 4°C overnight, followed by 
washing and incubation with appropriate 
secondary HRP labeled secondary antibody 
polymer (Vector Labs) for 30 min at room 
temperature. Signal development was 
accomplished by using the DAB Substrate Kit 
(Vector Laboratories). CD11b quantification was 
done by counting marker positive cells in four 
independent, randomly chosen areas analyzed at 
40x using a light microscope for each kidney 
tissue (n=3-5/treatment group). 
For immunofluorescence (IF) analyses, 
frozen tissue sections were prepared and fixed in -
20°C acetone before immunofluorescence staining 
and analyses. Sections were blocked at room 
temperature for 1h and incubated with the primary 
antibodies against total Notch-1 (polyclonal rabbit 
anti-Notch1, (cat # 100-401-407, 
Rockland, Limerick, PA), ErbB4 (polyclonal 
rabbit anti-ErBB4, cat # sc-283, C-18, Santa Cruz, 
Dallas, TX), EGFR (polyclonal rabbit anti-EGFR 
cat # 06-847, Millipore, Darmstadt, Germany), and 
synaptopodin (polyclonal goat, SC-21537, Santa 
Cruz) at 4°C overnight. Slides were incubated with 
appropriate fluorescently labeled secondary 
antibodies (Life Technologies, CA) and mounted 
with DAPI containing mounting solution (Vector 
Laboratories, Burlingame, CA). Fluorescence 
images were acquired using a Zeiss 700 LSM 
confocal microscope with a 20X objective and 
analyzed using the Zen software (Zeiss, Hartford, 
CT). Quantification was performed using ImageJ 
Software (NIH). 
Human samples-Human specimens and 
clinical data were from recently described studies 
(22,33). Briefly, kidney biopsy samples were 
collected from Southwestern American Indians 
enrolled in a randomized, placebo-controlled 
clinical trial to test the renoprotective efficacy of 
Losartan in early type 2 diabetic kidney disease 
(ClinicalTrials.gov no. NCT00340678). Glomeruli 
and tubulointerstitial fractions were isolated by 
microdissection, and the small RNA fraction was 
isolated using AllPrep kit (Qiagen). For expression 
analysis of miR-146a and the mRNAs, TaqMan 
primers (Applied Biosystems) and the 7900HT 
Fast Real-Time PCR System (Applied 
Biosystems) were used according to the 
manufacturer’s protocols as described. Patients 
with ACR<1g/mg were excluded. The small RNA 
fraction of the isolated RNA was used for 
construction of small RNA libraries. cDNA library 
preparation and multiplexed RNA sequencing was 
performed as previously described (22). This study 
was approved by the Review Board of the 
National Institute of Diabetes and Digestive and 
Kidney Diseases and each participant gave 
informed consent.  
miRNA expression profiling on human 
samples-miRNA profiling by quantitative real-
time PCR on human specimens from was 
performed as recently described using small RNA 
fraction (<200 nt) was isolated from micro-
dissected glomeruli and TaqMan miRNA assays 
(Applied Biosystems) (22). miRNA expression 
values, threshold cycle (CT), were normalized by 
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U6 small nuclear RNA (snRNA), and RNU44 and 
RNU48 small nucleolar RNA (snoRNA). Delta 
cycle time (ΔCT) was calculated by subtracting 
miRNAs’ CT from geometric mean of snRNA’s 
and snoRNA’s CT. 
For miRNA expression profiling by small 
RNA-sequencing, the isolated small RNA fraction, 
as above, was used for construction of small RNA 
libraries. cDNA library preparation and 
multiplexed RNA sequencing was performed as 
previously described (22,81,82). Data were 
analyzed as described (22), where the miRNA 
annotation was adopted from literature definitions 
and the reads from miRNAs that were at the same 
precursor cistronic transcription unit in the 
Genome were collapsed together into one miRNA 
cluster annotation. For normalization, the miRNA 
sequence reads were normalized by the total reads 
of each sample, as described (22). 
Statistical analysis-Data were analyzed 
using Excel (Microsoft, Redmond, WA) and Prism 
(GraphPad, San Diego, CA) softwares and were 
compared with using the Student’s t-test, where 
appropriate. P<0.05 was considered statistically 
significant.
 
ACKNOWLEDGEMENTS: We thank Hatem Elshabrawy, Saravana Kanagavelu, Steve Mangos, 
Andrew Armstrong, Isabel Fernandez, Prachal Bhargava, Dony Maiguel, Tristan Hays and Alex Braley 
for generous technical help with the podocyte cell-based assays, animal husbandry and for helpful 
discussions.  
 
CONFLICT OF INTEREST: V.G. and J.R. are inventors on pending patent applications related to this 
study. These authors and the Rush University Medical Center have the potential for financial benefit from 
their future commercialization. 
 
AUTHOR CONTRIBUTIONS: HWL, SQK, SJK, MHF designed and performed in vitro and in vivo 
experiments with erlotinib and analyzed data; HWL, MMA, TG and KHK performed western blots, PCR 
and qPCR and analyzed data; SQK, SJK, FG, KS, P-LT and TBH designed, performed and analyzed 
immunofluorescence studies; NJT performed TEM studies; DJC helped with histopathology; MHF, SJK, 
JLZ, LFM, DB and TBH helped design in vivo assays using miR-146a KO animals; MK, MB, JR and VG 
analyzed human data; VG designed and supervised the studies and HWL, SQK and VG co-wrote the 
paper. All authors reviewed and approved the final version of the manuscript. 
  
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 13 
REFERENCES 
 
1. (2003) USRDS: the United States Renal Data System. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 42, 1-230 
2. Wolf, G., Chen, S., and Ziyadeh, F. N. (2005) From the periphery of the glomerular capillary wall 
toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 
1626-1634 
3. Coward, R. J., Welsh, G. I., Yang, J., Tasman, C., Lennon, R., Koziell, A., Satchell, S., Holman, 
G. D., Kerjaschki, D., Tavare, J. M., Mathieson, P. W., and Saleem, M. A. (2005) The human 
glomerular podocyte is a novel target for insulin action. Diabetes 54, 3095-3102 
4. Remuzzi, G., Benigni, A., and Remuzzi, A. (2006) Mechanisms of progression and regression of 
renal lesions of chronic nephropathies and diabetes. The Journal of clinical investigation 116, 
288-296 
5. Godel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mor, A., 
Lindenmeyer, M. T., Rastaldi, M. P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., 
Kretzler, M., Wanke, R., Pavenstadt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Ruegg, M. 
A., Inoki, K., Walz, G., and Huber, T. B. (2011) Role of mTOR in podocyte function and diabetic 
nephropathy in humans and mice. The Journal of clinical investigation 121, 2197-2209 
6. Hartleben, B., Godel, M., Meyer-Schwesinger, C., Liu, S., Ulrich, T., Kobler, S., Wiech, T., 
Grahammer, F., Arnold, S. J., Lindenmeyer, M. T., Cohen, C. D., Pavenstadt, H., Kerjaschki, D., 
Mizushima, N., Shaw, A. S., Walz, G., and Huber, T. B. (2010) Autophagy influences glomerular 
disease susceptibility and maintains podocyte homeostasis in aging mice. The Journal of clinical 
investigation 120, 1084-1096 
7. Spurney, R. F., and Coffman, T. M. (2008) Stressed-out podocytes in diabetes? Journal of the 
American Society of Nephrology : JASN 19, 2035-2037 
8. Pagtalunan, M. E., Miller, P. L., Jumping-Eagle, S., Nelson, R. G., Myers, B. D., Rennke, H. G., 
Coplon, N. S., Sun, L., and Meyer, T. W. (1997) Podocyte loss and progressive glomerular injury 
in type II diabetes. The Journal of clinical investigation 99, 342-348 
9. Shankland, S. J. (2006) The podocyte's response to injury: role in proteinuria and 
glomerulosclerosis. Kidney international 69, 2131-2147 
10. Wiggins, R. C. (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. 
Kidney international 71, 1205-1214 
11. Mogensen, C. E., Chachati, A., Christensen, C. K., Close, C. F., Deckert, T., Hommel, E., 
Kastrup, J., Lefebvre, P., Mathiesen, E. R., Feldt-Rasmussen, B., and et al. (1985) 
Microalbuminuria: an early marker of renal involvement in diabetes. Uremia investigation 9, 85-
95 
12. Remuzzi, G., Macia, M., and Ruggenenti, P. (2006) Prevention and treatment of diabetic renal 
disease in type 2 diabetes: the BENEDICT study. Journal of the American Society of Nephrology 
: JASN 17, S90-97 
13. Kato, M., Park, J. T., and Natarajan, R. (2012) MicroRNAs and the glomerulus. Experimental cell 
research 318, 993-1000 
14. Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., 
Huang, X., Chang, A. N., Li, S., Kalra, A., Grafals, M., Portilla, D., MacKenna, D. A., Orkin, S. 
H., and Duffield, J. S. (2012) MicroRNA-21 promotes fibrosis of the kidney by silencing 
metabolic pathways. Science translational medicine 4, 121ra118 
15. Gebeshuber, C. A., Kornauth, C., Dong, L., Sierig, R., Seibler, J., Reiss, M., Tauber, S., Bilban, 
M., Wang, S., Kain, R., Bohmig, G. A., Moeller, M. J., Grone, H. J., Englert, C., Martinez, J., and 
Kerjaschki, D. (2013) Focal segmental glomerulosclerosis is induced by microRNA-193a and its 
downregulation of WT1. Nature medicine 19, 481-487 
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 14 
16. Zhang, Z., Peng, H., Chen, J., Chen, X., Han, F., Xu, X., He, X., and Yan, N. (2009) MicroRNA-
21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. 
FEBS letters 583, 2009-2014 
17. Chandrasekaran, K., Karolina, D. S., Sepramaniam, S., Armugam, A., Wintour, E. M., Bertram, J. 
F., and Jeyaseelan, K. (2012) Role of microRNAs in kidney homeostasis and disease. Kidney 
international 81, 617-627 
18. Ho, J., and Kreidberg, J. A. (2012) The long and short of microRNAs in the kidney. Journal of 
the American Society of Nephrology : JASN 23, 400-404 
19. Li, J. Y., Yong, T. Y., Michael, M. Z., and Gleadle, J. M. (2010) Review: The role of microRNAs 
in kidney disease. Nephrology 15, 599-608 
20. Long, J., Wang, Y., Wang, W., Chang, B. H., and Danesh, F. R. (2011) MicroRNA-29c is a 
signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in 
vivo knockdown prevents progression of diabetic nephropathy. The Journal of biological 
chemistry 286, 11837-11848 
21. Long, J., Wang, Y., Wang, W., Chang, B. H., and Danesh, F. R. (2010) Identification of 
microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic 
conditions. The Journal of biological chemistry 285, 23457-23465 
22. Lai, J. Y., Luo, J., O'Connor, C., Jing, X., Nair, V., Ju, W., Randolph, A., Ben-Dov, I. Z., Matar, 
R. N., Briskin, D., Zavadil, J., Nelson, R. G., Tuschl, T., Brosius, F. C., 3rd, Kretzler, M., and 
Bitzer, M. (2015) MicroRNA-21 in glomerular injury. Journal of the American Society of 
Nephrology : JASN 26, 805-816 
23. Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., and Baltimore, D. 
(2011) NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of 
myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of 
America 108, 9184-9189 
24. Taganov, K. D., Boldin, M. P., Chang, K. J., and Baltimore, D. (2006) NF-kappaB-dependent 
induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune 
responses. Proceedings of the National Academy of Sciences of the United States of America 103, 
12481-12486 
25. Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., 
Luong, M., Devrekanli, A., Xu, J., Sun, G., Tay, J., Linsley, P. S., and Baltimore, D. (2011) miR-
146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal 
of experimental medicine 208, 1189-1201 
26. Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N. Q., Scherr, M., 
Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noel, A., Martial, J. A., Hilfiker-
Kleiner, D., and Struman, I. (2013) MicroRNA-146a is a therapeutic target and biomarker for 
peripartum cardiomyopathy. The Journal of clinical investigation 123, 2143-2154 
27. Cheng, H. S., Sivachandran, N., Lau, A., Boudreau, E., Zhao, J. L., Baltimore, D., Delgado-
Olguin, P., Cybulsky, M. I., and Fish, J. E. (2013) MicroRNA-146 represses endothelial 
activation by inhibiting pro-inflammatory pathways. EMBO molecular medicine 5, 949-966 
28. Feng, B., Chen, S., McArthur, K., Wu, Y., Sen, S., Ding, Q., Feldman, R. D., and Chakrabarti, S. 
(2011) miR-146a-Mediated extracellular matrix protein production in chronic diabetes 
complications. Diabetes 60, 2975-2984 
29. Bhatt, K., Lanting, L. L., Jia, Y., Yadav, S., Reddy, M. A., Magilnick, N., Boldin, M., and 
Natarajan, R. (2015) Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic 
Nephropathy. Journal of the American Society of Nephrology : JASN  
30. Ichii, O., Otsuka, S., Sasaki, N., Namiki, Y., Hashimoto, Y., and Kon, Y. (2012) Altered 
expression of microRNA miR-146a correlates with the development of chronic renal 
inflammation. Kidney international 81, 280-292 
31. Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., 
Kamphorst, A. O., Landthaler, M., Lin, C., Socci, N. D., Hermida, L., Fulci, V., Chiaretti, S., Foa, 
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 15 
R., Schliwka, J., Fuchs, U., Novosel, A., Muller, R. U., Schermer, B., Bissels, U., Inman, J., 
Phan, Q., Chien, M., Weir, D. B., Choksi, R., De Vita, G., Frezzetti, D., Trompeter, H. I., 
Hornung, V., Teng, G., Hartmann, G., Palkovits, M., Di Lauro, R., Wernet, P., Macino, G., 
Rogler, C. E., Nagle, J. W., Ju, J., Papavasiliou, F. N., Benzing, T., Lichter, P., Tam, W., 
Brownstein, M. J., Bosio, A., Borkhardt, A., Russo, J. J., Sander, C., Zavolan, M., and Tuschl, T. 
(2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 
129, 1401-1414 
32. Boerries, M., Grahammer, F., Eiselein, S., Buck, M., Meyer, C., Goedel, M., Bechtel, W., 
Zschiedrich, S., Pfeifer, D., Laloe, D., Arrondel, C., Goncalves, S., Kruger, M., Harvey, S. J., 
Busch, H., Dengjel, J., and Huber, T. B. (2013) Molecular fingerprinting of the podocyte reveals 
novel gene and protein regulatory networks. Kidney international 83, 1052-1064 
33. Weil, E. J., Fufaa, G., Jones, L. I., Lovato, T., Lemley, K. V., Hanson, R. L., Knowler, W. C., 
Bennett, P. H., Yee, B., Myers, B. D., and Nelson, R. G. (2013) Effect of losartan on prevention 
and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 
62, 3224-3231 
34. Farazi, T. A., Horlings, H. M., Ten Hoeve, J. J., Mihailovic, A., Halfwerk, H., Morozov, P., 
Brown, M., Hafner, M., Reyal, F., van Kouwenhove, M., Kreike, B., Sie, D., Hovestadt, V., 
Wessels, L. F., van de Vijver, M. J., and Tuschl, T. (2011) MicroRNA sequence and expression 
analysis in breast tumors by deep sequencing. Cancer research 71, 4443-4453 
35. Weil, E. J., Lemley, K. V., Mason, C. C., Yee, B., Jones, L. I., Blouch, K., Lovato, T., 
Richardson, M., Myers, B. D., and Nelson, R. G. (2012) Podocyte detachment and reduced 
glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic 
nephropathy. Kidney international 82, 1010-1017 
36. Wharram, B. L., Goyal, M., Wiggins, J. E., Sanden, S. K., Hussain, S., Filipiak, W. E., Saunders, 
T. L., Dysko, R. C., Kohno, K., Holzman, L. B., and Wiggins, R. C. (2005) Podocyte depletion 
causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human 
diphtheria toxin receptor transgene. Journal of the American Society of Nephrology : JASN 16, 
2941-2952 
37. Meyer, T. W., Bennett, P. H., and Nelson, R. G. (1999) Podocyte number predicts long-term 
urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. 
Diabetologia 42, 1341-1344 
38. Hudkins, K. L., Pichaiwong, W., Wietecha, T., Kowalewska, J., Banas, M. C., Spencer, M. W., 
Muhlfeld, A., Koelling, M., Pippin, J. W., Shankland, S. J., Askari, B., Rabaglia, M. E., Keller, 
M. P., Attie, A. D., and Alpers, C. E. (2010) BTBR Ob/Ob mutant mice model progressive 
diabetic nephropathy. Journal of the American Society of Nephrology : JASN 21, 1533-1542 
39. Mei, J., Bachoo, R., and Zhang, C. L. (2011) MicroRNA-146a inhibits glioma development by 
targeting Notch1. Molecular and cellular biology 31, 3584-3592 
40. Bai, Y., Qian, C., Qian, L., Ma, F., Hou, J., Chen, Y., Wang, Q., and Cao, X. (2012) Integrin 
CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating 
microRNA-146a. Journal of immunology 188, 5293-5302 
41. Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, 
Y., Takanabe-Mori, R., Nishi, E., Hasegawa, K., Kita, T., and Kimura, T. (2010) Acute 
doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-
ErbB pathway. Cardiovascular research 87, 656-664 
42. Niranjan, T., Bielesz, B., Gruenwald, A., Ponda, M. P., Kopp, J. B., Thomas, D. B., and Susztak, 
K. (2008) The Notch pathway in podocytes plays a role in the development of glomerular disease. 
Nature medicine 14, 290-298 
43. Waters, A. M., Wu, M. Y., Onay, T., Scutaru, J., Liu, J., Lobe, C. G., Quaggin, S. E., and 
Piscione, T. D. (2008) Ectopic notch activation in developing podocytes causes 
glomerulosclerosis. Journal of the American Society of Nephrology : JASN 19, 1139-1157 
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 16 
44. Tao, R. H., and Maruyama, I. N. (2008) All EGF(ErbB) receptors have preformed homo- and 
heterodimeric structures in living cells. Journal of cell science 121, 3207-3217 
45. Sandholm, N., Salem, R. M., McKnight, A. J., Brennan, E. P., Forsblom, C., Isakova, T., McKay, 
G. J., Williams, W. W., Sadlier, D. M., Makinen, V. P., Swan, E. J., Palmer, C., Boright, A. P., 
Ahlqvist, E., Deshmukh, H. A., Keller, B. J., Huang, H., Ahola, A. J., Fagerholm, E., Gordin, D., 
Harjutsalo, V., He, B., Heikkila, O., Hietala, K., Kyto, J., Lahermo, P., Lehto, M., Lithovius, R., 
Osterholm, A. M., Parkkonen, M., Pitkaniemi, J., Rosengard-Barlund, M., Saraheimo, M., Sarti, 
C., Soderlund, J., Soro-Paavonen, A., Syreeni, A., Thorn, L. M., Tikkanen, H., Tolonen, N., 
Tryggvason, K., Tuomilehto, J., Waden, J., Gill, G. V., Prior, S., Guiducci, C., Mirel, D. B., 
Taylor, A., Hosseini, S. M., Group, D. E. R., Parving, H. H., Rossing, P., Tarnow, L., Ladenvall, 
C., Alhenc-Gelas, F., Lefebvre, P., Rigalleau, V., Roussel, R., Tregouet, D. A., Maestroni, A., 
Maestroni, S., Falhammar, H., Gu, T., Mollsten, A., Cimponeriu, D., Ioana, M., Mota, M., Mota, 
E., Serafinceanu, C., Stavarachi, M., Hanson, R. L., Nelson, R. G., Kretzler, M., Colhoun, H. M., 
Panduru, N. M., Gu, H. F., Brismar, K., Zerbini, G., Hadjadj, S., Marre, M., Groop, L., Lajer, M., 
Bull, S. B., Waggott, D., Paterson, A. D., Savage, D. A., Bain, S. C., Martin, F., Hirschhorn, J. 
N., Godson, C., Florez, J. C., Groop, P. H., and Maxwell, A. P. (2012) New susceptibility loci 
associated with kidney disease in type 1 diabetes. PLoS genetics 8, e1002921 
46. Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, 
E., Bleich, M., Grone, H. J., Nelson, P. J., Schlondorff, D., Cohen, C. D., Kretzler, M., and 
European Renal c, D. N. A. B. C. (2006) Modular activation of nuclear factor-kappaB 
transcriptional programs in human diabetic nephropathy. Diabetes 55, 2993-3003 
47. Bollee, G., Flamant, M., Schordan, S., Fligny, C., Rumpel, E., Milon, M., Schordan, E., Sabaa, 
N., Vandermeersch, S., Galaup, A., Rodenas, A., Casal, I., Sunnarborg, S. W., Salant, D. J., 
Kopp, J. B., Threadgill, D. W., Quaggin, S. E., Dussaule, J. C., Germain, S., Mesnard, L., 
Endlich, K., Boucheix, C., Belenfant, X., Callard, P., Endlich, N., and Tharaux, P. L. (2011) 
Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly 
progressive crescentic glomerulonephritis. Nature medicine 17, 1242-1250 
48. Chen, J., Chen, J. K., and Harris, R. C. (2015) EGF receptor deletion in podocytes attenuates 
diabetic nephropathy. Journal of the American Society of Nephrology : JASN 26, 1115-1125 
49. Zhang, M. Z., Wang, Y., Paueksakon, P., and Harris, R. C. (2014) Epidermal growth factor 
receptor inhibition slows progression of diabetic nephropathy in association with a decrease in 
endoplasmic reticulum stress and an increase in autophagy. Diabetes 63, 2063-2072 
50. Advani, A., Wiggins, K. J., Cox, A. J., Zhang, Y., Gilbert, R. E., and Kelly, D. J. (2011) 
Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates 
albuminuria in experimental diabetic nephropathy. Nephrology 16, 573-581 
51. Alpers, C. E., and Hudkins, K. L. (2011) Mouse models of diabetic nephropathy. Current opinion 
in nephrology and hypertension 20, 278-284 
52. Brosius, F. C., 3rd, Alpers, C. E., Bottinger, E. P., Breyer, M. D., Coffman, T. M., Gurley, S. B., 
Harris, R. C., Kakoki, M., Kretzler, M., Leiter, E. H., Levi, M., McIndoe, R. A., Sharma, K., 
Smithies, O., Susztak, K., Takahashi, N., Takahashi, T., and Animal Models of Diabetic 
Complications, C. (2009) Mouse models of diabetic nephropathy. Journal of the American 
Society of Nephrology : JASN 20, 2503-2512 
53. Breyer, M. D., Redha, R., and Breyer, J. A. (1990) Segmental distribution of epidermal growth 
factor binding sites in rabbit nephron. The American journal of physiology 259, F553-558 
54. Chen, J., Chen, J. K., Nagai, K., Plieth, D., Tan, M., Lee, T. C., Threadgill, D. W., Neilson, E. G., 
and Harris, R. C. (2012) EGFR signaling promotes TGFbeta-dependent renal fibrosis. Journal of 
the American Society of Nephrology : JASN 23, 215-224 
55. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., 
Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity. 
Nature biotechnology 29, 1046-1051 
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 17 
56. Bottinger, E. P., and Bitzer, M. (2002) TGF-beta signaling in renal disease. Journal of the 
American Society of Nephrology : JASN 13, 2600-2610 
57. Schiffer, M., Bitzer, M., Roberts, I. S., Kopp, J. B., ten Dijke, P., Mundel, P., and Bottinger, E. P. 
(2001) Apoptosis in podocytes induced by TGF-beta and Smad7. The Journal of clinical 
investigation 108, 807-816 
58. Lee, H. W., Khan, S. Q., Faridi, M. H., Wei, C., Tardi, N. J., Altintas, M. M., Elshabrawy, H. A., 
Mangos, S., Quick, K. L., Sever, S., Reiser, J., and Gupta, V. (2015) A Podocyte-Based 
Automated Screening Assay Identifies Protective Small Molecules. Journal of the American 
Society of Nephrology : JASN 26, 2741-2752 
59. Wu, D. T., Bitzer, M., Ju, W., Mundel, P., and Bottinger, E. P. (2005) TGF-beta concentration 
specifies differential signaling profiles of growth arrest/differentiation and apoptosis in 
podocytes. Journal of the American Society of Nephrology : JASN 16, 3211-3221 
60. Xavier, S., Niranjan, T., Krick, S., Zhang, T., Ju, W., Shaw, A. S., Schiffer, M., and Bottinger, E. 
P. (2009) TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes. 
Journal of the American Society of Nephrology : JASN 20, 2127-2137 
61. Susztak, K., Raff, A. C., Schiffer, M., and Bottinger, E. P. (2006) Glucose-induced reactive 
oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic 
nephropathy. Diabetes 55, 225-233 
62. Liu, N., Guo, J. K., Pang, M., Tolbert, E., Ponnusamy, M., Gong, R., Bayliss, G., Dworkin, L. D., 
Yan, H., and Zhuang, S. (2012) Genetic or pharmacologic blockade of EGFR inhibits renal 
fibrosis. Journal of the American Society of Nephrology : JASN 23, 854-867 
63. Suzuki, H. I., Arase, M., Matsuyama, H., Choi, Y. L., Ueno, T., Mano, H., Sugimoto, K., and 
Miyazono, K. (2011) MCPIP1 ribonuclease antagonizes dicer and terminates microRNA 
biogenesis through precursor microRNA degradation. Molecular cell 44, 424-436 
64. Qu, B., Cao, J., Zhang, F., Cui, H., Teng, J., Li, J., Liu, Z., Morehouse, C., Jallal, B., Tang, Y., 
Guo, Q., Yao, Y., and Shen, N. (2015) Type I Interferon Inhibition of MicroRNA-146a 
Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in 
Systemic Lupus Erythematosus. Arthritis & rheumatology 67, 3209-3218 
65. Lee, E. Y., Chung, C. H., Khoury, C. C., Yeo, T. K., Pyagay, P. E., Wang, A., and Chen, S. 
(2009) The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases 
podocyte motility and albumin permeability. American journal of physiology. Renal physiology 
297, F85-94 
66. Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999) Notch signaling: cell fate control 
and signal integration in development. Science 284, 770-776 
67. Cheng, H. T., Kim, M., Valerius, M. T., Surendran, K., Schuster-Gossler, K., Gossler, A., 
McMahon, A. P., and Kopan, R. (2007) Notch2, but not Notch1, is required for proximal fate 
acquisition in the mammalian nephron. Development 134, 801-811 
68. Barak, H., Surendran, K., and Boyle, S. C. (2012) The role of Notch signaling in kidney 
development and disease. Advances in experimental medicine and biology 727, 99-113 
69. Sirin, Y., and Susztak, K. (2012) Notch in the kidney: development and disease. The Journal of 
pathology 226, 394-403 
70. Carpenter, G. (2003) ErbB-4: mechanism of action and biology. Experimental cell research 284, 
66-77 
71. Veikkolainen, V., Naillat, F., Railo, A., Chi, L., Manninen, A., Hohenstein, P., Hastie, N., Vainio, 
S., and Elenius, K. (2012) ErbB4 modulates tubular cell polarity and lumen diameter during 
kidney development. Journal of the American Society of Nephrology : JASN 23, 112-122 
72. Zeng, F., Zhang, M. Z., Singh, A. B., Zent, R., and Harris, R. C. (2007) ErbB4 isoforms 
selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. 
Molecular biology of the cell 18, 4446-4456 
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 18 
73. Coaxum, S. D., Garnovskaya, M. N., Gooz, M., Baldys, A., and Raymond, J. R. (2009) 
Epidermal growth factor activates Na(+/)H(+) exchanger in podocytes through a mechanism that 
involves Janus kinase and calmodulin. Biochimica et biophysica acta 1793, 1174-1181 
74. Zeng, F., Miyazawa, T., Kloepfer, L. A., and Harris, R. C. (2014) Deletion of ErbB4 accelerates 
polycystic kidney disease progression in cpk mice. Kidney international 86, 538-547 
75. Lu, L. F., Boldin, M. P., Chaudhry, A., Lin, L. L., Taganov, K. D., Hanada, T., Yoshimura, A., 
Baltimore, D., and Rudensky, A. Y. (2010) Function of miR-146a in controlling Treg cell-
mediated regulation of Th1 responses. Cell 142, 914-929 
76. Shankland, S. J., Pippin, J. W., Reiser, J., and Mundel, P. (2007) Podocytes in culture: past, 
present, and future. Kidney international 72, 26-36 
77. Mundel, P., Reiser, J., Zuniga Mejia Borja, A., Pavenstadt, H., Davidson, G. R., Kriz, W., and 
Zeller, R. (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation 
during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236, 
248-258 
78. Saleem, M. A., O'Hare, M. J., Reiser, J., Coward, R. J., Inward, C. D., Farren, T., Xing, C. Y., Ni, 
L., Mathieson, P. W., and Mundel, P. (2002) A conditionally immortalized human podocyte cell 
line demonstrating nephrin and podocin expression. Journal of the American Society of 
Nephrology : JASN 13, 630-638 
79. Wei, C., Moller, C. C., Altintas, M. M., Li, J., Schwarz, K., Zacchigna, S., Xie, L., Henger, A., 
Schmid, H., Rastaldi, M. P., Cowan, P., Kretzler, M., Parrilla, R., Bendayan, M., Gupta, V., 
Nikolic, B., Kalluri, R., Carmeliet, P., Mundel, P., and Reiser, J. (2008) Modification of kidney 
barrier function by the urokinase receptor. Nature medicine 14, 55-63 
80. Chen, H., Yang, K., Choi, S., Fischer, J. H., and Jeong, H. (2009) Up-regulation of UDP-
glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased 
lamotrigine elimination in pregnancy. Drug metabolism and disposition: the biological fate of 
chemicals 37, 1841-1847 
81. Ben-Dov, I. Z., Muthukumar, T., Morozov, P., Mueller, F. B., Tuschl, T., and Suthanthiran, M. 
(2012) MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial 
fibrosis. Transplantation 94, 1086-1094 
82. Farazi, T. A., Brown, M., Morozov, P., Ten Hoeve, J. J., Ben-Dov, I. Z., Hovestadt, V., Hafner, 
M., Renwick, N., Mihailovic, A., Wessels, L. F., and Tuschl, T. (2012) Bioinformatic analysis of 
barcoded cDNA libraries for small RNA profiling by next-generation sequencing. Methods 58, 
171-187 
 
  
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
miR-146 in podocytes and diabetic injury 
 19 
FOOTNOTES 
This work was supported in part by NIH Grants R01DK084195, R01HL109582 (to V.G.) and 
R01DK106512 and R01DK107984 (to V.G. and J.R.), the Nephcure Foundation and with resources from 
the Rush University Medical Center.  
 
FIGURE LEGENDS 
 
FIGURE 1. Down-regulation of miR-146a correlates with increased albuminuria in diabetic patients. A-
B. Scatter plots showing correlation between relative expression of miR-146a v/s urinary albumin to 
creatinine ratio (ACR) in the isolated glomeruli of kidney biopsies from diabetic patients (n=45). Each 
dot represents an individual patient. Data are from two time-points; one at the time of biopsy (A) and one 
at the end of observation period (5±1 yrs post-biopsy, B). Relative miR146a level of 0.4 is shown to 
divide the plot into two groups with different ACR values.  
 
FIGURE 2. miR-146a levels are reduced in the diabetic human and mouse kidney glomeruli. A-B. 
Representative in situ hybridization (ISH) images of human (A) and mouse (B) kidney sections to detect 
expression pattern of miR-146a (indicated with an arrow). Each kidney section was stained with the 
indicated probe (against miR-146a, a scrambled control or against U6 RNA). Confocal images of 
immunofluorescently labeled glomeruli (A), stained with the podocyte marker synaptopodin (Synpo, 
green), show relative podocyte density in the representative healthy and diabetic human kidney sections. 
Representative ISH images of kidney sections from C57BL/6 WT and miR-146a-/- animals stained with 
specific probe against miR-146a are also shown (B). Scale bar, 50 µm (A, B). C. A bar graph showing 
urinary albumin to creatinine ratio (ACR) in 12 wk old BTBR WT and BTBR ob/ob animals. Data shown 
are mean ± the standard error of the mean (SEM) (n=5/group). ***, P<0.001. D. A bar graph showing 
relative expression level of miR-146a in kidney sections from 12 wk old BTBR WT and BTBR ob/ob 
mice, as measured by qRT-PCR. Data shown are mean ± SEM (n=3). *, P<0.05. 
 
FIGURE 3. miR-146a targets Notch-1 and ErbB4 are upregulated in the diseased glomeruli. A. Primary 
sequence and predicted secondary structure of pre-mir-146a. miRNA is transcribed in the nucleus as 
primary miRNA, processed by endonuclease Drosha into pre-miRNA, exported into the cytoplasm, where 
it is cleaved by RNase Dicer to yield a mature 22-nt duplex miRNA. The sequence of 22-nucleotide (22-
nt) mature miR-146a duplex is highlighted in red and blue. Typically, only one strand of the 22-nt duplex 
gets loaded into an RNA-induced silencing complex (RISC) to suppress target gene expression. In miR-
146a, this is typically the 5’-strand (shown in red), also known as miR-146a-5p. B. Alignment of miR-
146a target sites in the 3’ UTRs of Notch-1 and ErbB4 mRNA.(26,40) C. Graph showing relative 
expression levels of ErbB4 mRNA in various human kidney biopsies, data derived from Schmid et al.(46) 
The published microarray data was generated using renal biopsies from patients with histological 
evidence of DN (n=13), where the biopsies from cadaveric donors (n=4), related living donors (n=3) and 
from patients with minimal change disease (MCD) (n=4) without histological or clinical evidence of 
impaired renal function served as controls. Data shown are mean ± SEM. ****, P<0.0001. D. 
Representative images showing histochemical analyses of kidney tissue samples from 12 wk old BTBR 
WT (healthy) and BTBR ob/ob (diabetic) mice using periodic acid-Schiff (PAS) and Masson trichrome 
(trichrome) staining showing increased mesangial sclerosis and fibrosis in the diabetic kidneys. Scale bar, 
50µm. E. Expression of EGFR, Notch-1 and ErbB4 is upregulated in the glomeruli of BTBR ob/ob mice. 
Representative confocal microscopy images of immunofluorescently labeled glomeruli from 12 wk old 
BTBR WT (healthy) and BTBR ob/ob (diabetic) mice. Kidney sections were imaged after staining with 
DAPI and antibodies against EGFR, Notch-1, ErbB4 and Synaptopodin (Synpo). Merged DAPI, EGFR 
and Synpo, DAPI, Notch-1 and Synpo, and DAPI, ErbB4 and Synpo channels are also presented that 
show podocyte colocalization for these proteins. Scale bar, 50 µm. F. Expression of EGFR, Notch-1 and 
ErbB4 is upregulated in the glomeruli of diabetic patients. Representative images showing histochemical 
analyses of kidney tissue samples (left panels) after PAS and trichrome staining showing extensive 
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glomerular expansion, mesangial sclerosis and fibrosis in the diabetic kidneys. Scale bar, 50 µm. 
Representative confocal microscopy images of immunofluorescently labeled kidney sections that imaged 
after staining with DAPI and antibodies against EGFR, Notch-1, ErbB4 and Synpo (Right panels). 
Merged EGFR and Synpo, Notch-1 and Synpo, and ErbB4 and Synpo channels are shown that show 
podocyte colocalization for these proteins, respectively. Scale bar, 50 µm. Bottom panels present higher-
magnification views of boxed regions in the middle panel. G. miR-146a reduces the activity of luciferase 
linked with 3’ UTRs of ErbB4 and Notch1. Bar graph reporting results from luciferase activity assay from 
HEK293T cells co-transfected with pre-miR-146a or pre-miR-control and a luciferase reporter plasmid 
containing either the WT or mutated (mut) sequence of 3’ UTRs of ErbB4 or Notch-1. Luciferase activity 
was normalized with the activity of β-galactosidase from a co-transfected plasmid. Data shown are mean 
± SEM (n = 4).  *, P<0.05. ***, P <0.0005. 
 
FIGURE 4. Erlotinib attenuates accelerated development of STZ-induced albuminuria in miR-146a-/- 
animals. A. Both WT and miR-146a-/- animals developed similar and sustained levels of hyperglycemia 
within 2 weeks of STZ treatment. Treatment with erlotinib starting at 4 wks after STZ-induction did not 
result in any change in level of hyperglycemia in either strain. Blood glucose levels remained unchanged 
in the untreated WT and miR146-/- mice. Data presented on these graphs are mean ± SEM (n=3-
10/group). B. WT and miR-146a-/- animals displayed equal levels of weight loss upon STZ-induced 
hyperglycemia that was unaffected by treatment with erlotinib. Data presented on these graphs are mean 
body weight at the end of the experiment (16 wks post STZ) ± SEM (n=3-10/group). C. miR-146a-/- 
animals showed increased albuminuria after approximately 8 wks post-STZ and a significantly increased 
albuminuria 14 wks post-STZ, as compared to the WT animals. Treatment with erlotinib significantly 
reduced the development of albuminuria and both the WT and the miR-146a-/- animals. Data shown are 
mean ± SEM (n=4-10/group). *,#, P<0.05. 
 
FIGURE 5. STZ-induced hyperglycemia increases glomerulopathy and foot process effacement in the 
mouse glomeruli that is suppressed by erlotinib. A. Representative images showing PAS-stained kidney 
tissue samples from WT and miR-146a-/- animals treated with vehicle alone (Control), STZ and vehicle 
(STZ) or STZ and erlotinib (STZ + Erl) and analyzed 16 wks post-STZ showing increased mesangial 
sclerosis in STZ-treated animals that is reduced with erlotinib treatment. Scale bar, 50µm. B. Graphs 
showing quantification of mesangial matrix expansion from the PAS-stained sections in A. Data shown 
are normalized to the level of staining in control tissue and are mean ± SEM (n=3-5/group). *, P<0.05, 
**, P<0.01, ***, P<0.001. C. Erlotinib protects against STZ-induced podocyte foot process (FP) 
effacement. Representative electron microscopy images of WT (top panels) and miR-146a-/- (bottom 
panels) mouse glomeruli treated with vehicle alone (Control), with STZ and vehicle (STZ) or with STZ 
and erlotinib (STZ + Erl). Scale bar, 2 µm. FP=foot processes; BM = basement membrane. A higher 
magnification view is presented below every image. Scale bar, 500 nm. A graph on the right shows 
quantification of the number of FPs per unit glomerular length in each of the samples. Data shown are 
mean ± SEM (n = 3/group) and significant difference comparison was performed as compared to the 
respective controls.  *, P<0.05, **, P<0.01, ns = not significant.  
 
FIGURE 6. STZ treatment of WT and miR-146a-/- mice results in increased glomerular injury and 
induction of miR-146a targets in the mouse glomeruli that is suppressed by erlotinib. A. STZ-induced 
upregulation of EGFR, Notch-1 and ErbB4 expression in the mouse glomeruli is reduced by erlotinib. 
Representative confocal microscopy images of immunofluorescently labeled glomeruli from WT (top 
panels) and miR-146a-/- (bottom panels) mice treated with vehicle alone (Control), with STZ and vehicle 
(STZ) or with STZ and erlotinib (STZ + Erl). Kidney sections were imaged after staining with DAPI and 
antibodies against EGFR, Notch-1, ErbB4 and Synaptopodin (Synpo). Merged DAPI, EGFR and Synpo, 
DAPI, Notch-1 and Synpo, and DAPI, ErbB4 and Synpo channels are also presented that show podocyte 
colocalization for these proteins. Scale bar, 50 µm. B. Graphs showing the quantification of relative 
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glomerular signal intensity of EGFR, Notch-1 and ErbB4 in samples from A. Data shown are mean ± 
SEM (n=5/group). ns = not significant, **, P<0.01, ***, P<0.001, ****, P<0.0001. 
 
FIGURE 7. Reduction in glomerular miR-146a levels and podocyte numbers by STZ treatment is 
suppressed by erlotinib. A. Representative ISH images of kidney sections from WT mice treated with 
vehicle alone (Control), with STZ and vehicle (STZ) or with STZ and erlotinib (STZ + Erl) and stained to 
detect expression pattern of miR-146a show protection of glomerular miR-146a levels by erlotinib. Each 
kidney section was stained with the indicated probe (against miR-146a, a scrambled control, or against 
U6 RNA). Representative ISH image of kidney sections from miR-146a-/- animals stained with specific 
probe against miR-146a is also shown. Scale bar, 50µm. B. Erlotinib protects against STZ-induced 
podocyte loss. Representative immunohistochemical images of glomeruli stained with an antibody against 
WT1 from WT mice treated with vehicle alone (Control), with STZ and vehicle (STZ) or with STZ and 
erlotinib (STZ + Erl). Scale bar, 50 µm. Graph on the right shows quantification of WT1 positive cells per 
glomeruli in these samples. Data shown is mean ± SEM (n=3). *, P<0.05, ****, P<0.0001. 
 
FIGURE 8. Pan-ErbB inhibitor suppresses inflammation by rescuing podocyte expression of miR-146a 
and suppressing its targets Notch-1 and ErbB4. A. TGF-β1 treatment reduces F-actin fibers in cultured 
podocytes and erlotinib protects against this loss. Representative confocal microscopy images of cultured 
mouse podocytes treated with vehicle alone (Control), TGF-β1 (5ng/mL), or with TGF-β1 (5ng/mL) and 
erlotinib (10µM) for 24 hrs and stained with CellMask blue (nuclear stain) and Alexa Flour568-labeled 
phalloidin (to stain F-actin fibers). Scale bar, 20µm. B. TGF-β1 treatment induces expression of Notch-1 
and ErbB4 in cultured WT and miR-146a-/- podocytes and erlotinib suppresses it. Immunoblot analysis of 
various phosphorylated (p-) and total proteins in the lysates from WT and miR-146a-/- podocytes 
stimulated without or with 5ng/mL TGF-β1 (TGF-β1) in the absence or presence of erlotinib (10µM). 
GAPDH was used as the loading control. Relative position of the molecular weight markers is shown on 
the left.  
 
FIGURE 9. TGF-β1 induced upregulation of MCP-1 expression in podocytes is suppressed by erlotinib. 
A bar graph showing relative expression level of MCP-1 in WT podocytes treated with vehicle DMSO 
(Control), 10µM erlotinib (Erl), 5ng/mL TGF-β1 (TGF-b1) or 5ng/mL TGF-β1 and 10µM erlotinib 
(TGF-β1 + Erl) for 24h, as measured by qRT-PCR. Data was normalized using GAPDH mRNA controls 
and are mean ± SEM (n=3). **, P<0.005. 
 
FIGURE 10. Working Model. A diagram showing our working model. Under homeostatic conditions of 
normoglycemia, podocyte expressed miR-146a suppresses expression of Notch-1 and ErbB4 to maintain 
healthy cells. Diabetic milieu, including TGF-β1 (and MCP-1), induces MCP1 and MCPIP1 in podocytes, 
which decreases miR-146a levels. This results in de-repression of Notch-1 and ErbB4, which together 
with EGFR, induce podocyte injury. Blocking this signaling pathway with ErbB4/EGFR inhibitors 
suppresses the harmful signaling and decreases podocyte injury in vitro and glomerulopathy in vivo. 
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Supplementary Materials 
 
Supplementary Figures 
 
Figure S1. Reduction in glomerular miR-146a levels correlate with progression to higher albuminuria in 
diabetic patients. 
 
Figure S2. Expression level of podocyte markers Nephrin and WT1 are reduced in the kidney sections of 
diabetic mice. 
 
Figure S3. Expression level of miR-146a and its targets in primary podocytes.  
 
Figure S4. WB analysis of ErbB4 expression level in primary podocytes and murine kidney sections.  
 
Figure S5. Schematic of the luciferase reporter assay. 
 
Figure S6. Ectopic expression of miR-146a results in reduced ErbB4 expression in murine podocytes. 
 
Figure S7. STZ treatment increases renal leukocyte infiltration that is suppressed by erlotinib. 
 
Figure S8. ErbB4 and EGFR heterodimerize in cells.  
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Figure S1. Reduction in glomerular miR-146a levels correlate with progression to higher 
albuminuria in diabetic patients. A-B. Two graphs showing change in urinary albumin to creatinine 
ratio (ACR) in diabetic patients (n=45) over 5±1 years (T1= initial ACR measurement, at the time of 
kidney biopsy, T2 = second ACR measurement 5±1 years later), where patients with relative glomerular 
miR-146a levels of >0.4 show slower increase in ACR over this time period and patients with relative 
miR-146a levels of <0.4 show progression to a higher level of ACR over the same period. Each dot 
represents an individual patient. Significance of difference between the two sets was determined using 
student’s t-test. 
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Figure S2. Expression level of podocyte markers Nephrin and WT1 are reduced in the kidney 
sections of diabetic mice. Bar graphs showing relative expression levels of Nephrin and WT1 in the 
kidney sections from 12 wk old BTBR WT and BTBR ob/ob mice, as measured by qRT-PCR. Their 
expression was normalized with Gapdh mRNA expression. Data shown are mean ± SEM (n=3). *, 
P<0.05.  
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Figure S3. Expression level of miR-146a and its targets in primary podocytes. A. A bar graph 
showing relative expression level of miR-146a in the kidney sections from 10-12 wk old WT and miR-
146a-/- mice, as measured by qRT-PCR. Their expression was normalized using miR-361 miRNA 
expression. Data shown are mean ± SEM (n=3). *, P<0.05. B. Bar graphs showing relative expression 
level of miR-146a targets ErbB4 and Notch-1 in the primary podocytes isolated from the glomeruli of 10-
12 wk old WT and miR-146a-/- mice, as measured by qRT-PCR. Their expression was normalized using 
GAPDH mRNA expression. Expression level of EGFR, not a miR-146a target, was not changed. Data 
shown are mean ± SEM (n=3). **, P<0.01, *, P<0.05.  
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Figure S4. WB analysis of ErbB4 expression level in primary podocytes and murine kidney sections. 
ErbB4 levels are basally increased in miR-146a-/- samples. Immunoblot analysis of total ErbB4 protein in 
the lysates from isolated glomeruli of WT or miR-146a-/- (-/-) animals (left blot) or lysates of cultured 
primary podocytes from isolated glomeruli of WT and miR-146a-/- (-/-) (right blot). β-actin was used as 
the loading control. Relative position of the molecular weight markers is shown on the left. 
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Figure S5. Schematic of the luciferase reporter assay. A. Schematic graph of luciferase reporter assay. 
Luciferase expression plasmid contains 3’-UTR sequence of our interest at the 3’-end of luciferase gene. 
Transfection of the luciferase expression plasmid into HEK293T cells produces the luciferase mRNA 
with 3’-UTR of our interest. In the absence of a specific miR-146a sequence to suppress the 3’ -UTR, the 
luciferase protein product is produced, which can be detected using a luciferase assay. However, in the 
presence of a co-transfected miR-146a construct, and if this construct recognizes the inserted 3’-UTR 
sequence, the translation of luciferase mRNA is suppressed and the expression and activity of luciferase is 
reduced, which can be measured using a luciferase assay system. B. Sequence of the wide type and 
mutated 3’-UTRs of ErbB4 and Notch1 that were inserted in the luciferase vector are listed. 
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Figure S6. Ectopic expression of miR-146a results in reduced ErbB4 expression in murine 
podocytes. Immunoblot analysis of total ErbB4 protein in the lysates from cultured WT podocytes 
transduced with viral particles containing plasmids that express either miR-146a or a scrambled sequence. 
GAPDH was used as the loading control. Relative position of the molecular weight markers is shown on 
the left. 
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Figure S7. STZ treatment increases renal leukocyte infiltration that is suppressed by erlotinib. 
Diabetic milieu increases inflammation and tissue infiltration of leukocytes. Representative 
immunohistochemical images of anti-CD11b antibody stained murine kidney sections from WT (left 
panels) and miR-146a-/- (right panels) mice treated with vehicle alone (Control), with STZ and vehicle 
(STZ) or with STZ and erlotinib (STZ + Erl) at the end of the experiment (16 weeks post-STZ) and show 
increased leukocyte infiltration in the STZ-treated tissues, which is reduced in the STZ and erlotinib 
group. Images were taken at 40X magnification. Scale bar, 50 µm. A bar graph below shows 
quantification of CD11b positive cells in four independent, randomly selected fields observed at 10X 
magnification. Data shown are mean ± SEM (n=3-5/grp). *, P<0.05; **, P<0.01. 
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Figure S8. ErbB4 and EGFR heterodimerize in cells. A. HEK293T cells were transfected with the 
plasmids expressing either EGFR or human ErbB4 and EGFR (as indicated) and cultured for 2 days. 
Subsequently, the lysates were immunoprecipitated with antibody against ErbB4 or an isotype control 
according to literature protocols. The immunoprecipitated extracts were immunoblotted (IB) for EGFR or 
ErbB4 using specific antibodies to study co-immunoprecipitation of ErbB4 with EGFR. Total cell lysates 
were used as a control to confirm expression of each protein. Relative position of the molecular weight 
markers is shown on the left. 
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